HCPCS Level II code J2916 denotes a 12.5 mg unit of sodium ferric gluconate complex in sucrose injection, an intravenous iron therapy used for patients with iron deficiency when oral therapy is inadequate. This code is nationally relevant because intravenous iron therapies are commonly administered in outpatient infusion settings and impact drug utilization, billing practices, and payer coverage policies across commercial and public payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmark information on utilization and reimbursement patterns, summaries of payer coverage approaches, and clinical context describing typical administration settings and indications. The content highlights billing considerations for infusion administration and unit reporting, and flags areas where payers commonly apply medical necessity criteria or prior authorization requirements.

This publication provides practical reference material for revenue cycle, clinical, and policy teams seeking a concise briefing on J2916: what the code represents, where the service is typically delivered, and the payer landscape that influences access and billing. Data not available in the input is noted where applicable.